Baxter To Divest Vero Cell Technology and Assets to Nanotherapeutics

Baxter International Inc. has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed.

The Vero cell platform is an advanced, cell-based technology for vaccines production. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus.

Baxter recently completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer Inc.

Source: Baxter International

Leave a Reply

Your email address will not be published. Required fields are marked *